Cancer is a dynamic disease and becomes heterogeneous during the progression. The heterogeneity of tumor will result in distinct molecular signatures with different degree of sensitivities to the treatments that might be precisely monitored by non-invasive imaging modalities such as PET/SPECT/CT. These imaging results may help us not only knowing more of cancer itself but also may precisely detected the targets of tumors for further effective drug development and patient stratification.
In this webinar, Dr. Pradip Chaudhari, will give insights into how to identify and localize the tumor in the animal model, to characterize the tumor by specific molecular target, to monitor the intricate pathways in tumorigenesis and to evaluate the treatment outcome by non-invasive preclinical PET/SPECT/CT image. These image results are not limited in the preclinical application but may move to the clinical end for further drug development and patient selection.
In Dr. Gabriela Kramer-Marek’s talk, she will address on targeted molecular image in cancer by board range of targeted -PET radiotracer to select patients accuratly, to understand intrinsic resistance mechanisms or the emergence of acquired resistance following treatment initiation and to choose the most effective combination regimen in circumstances in which single-agent therapies are insufficiently effective. These works will enable smart monitoring of immunotherapies and expand opportunities for personalized medicine approaches.
Dr. Chaudhari will focus on how to use preclinical PET/SPECT/CT for basic research of cancer biology and anti-cancer drug development. Dr. Kramer-Marek will discuss affibody-based PET agents as potential new imaging biomarkers for personalized assessment of drug resistance and early prediction of patient treatment responses.
The webinar would appeal to basic biologists, radiochemists, clinicians and drug developers interested in the applications of non-invasive image in translational cancer research, cancer immunotherapies and personalized medicine. Researchers in the field of cancer biology and immunotherapy who are interested in immune checkpoint inhibitors would also benefit.
Dr. P. R. Chaudhari
Senior Scientist, Comparative Oncology & Small Animal Imaging Facility, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai
Dr Gabriela Kramer-Marek